Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3,130	2,809	2,093	1,517	1,123	789.39
Other Revenue	7.75	7.75	7.74	10	9.51	4.54
Revenue	3,138	2,817	2,100	1,527	1,132	793.93
Revenue Growth (YoY)	31.49%	34.13%	37.55%	34.86%	42.61%	8.81%
Cost of Revenue	212.12	184.47	140.2	171.01	126.99	85.65
Gross Profit	2,926	2,633	1,960	1,356	1,005	708.29
Selling, General & Admin	1,513	1,393	1,060	841.02	700.65	503.55
Research & Development	352.79	292.02	228.52	148.58	79.74	74.23
Other Operating Expenses	13.96	13.3	10.95	7.64	5.55	3.83
Operating Expenses	1,882	1,702	1,300	995.83	783.6	581.42
Operating Income	1,044	930.33	659.88	360.06	221.64	126.86
Interest Expense	-0.6	-0.45	-0.51	-0.62	-1.07	-2.46
Interest & Investment Income	8.3	6.99	10.17	8.09	7.84	3.67
Currency Exchange Gain (Loss)	0.11	-0.12	-1.03	0.48	-0.47	-0.95
Other Non Operating Income (Expenses)	20	-0.09	-0.39	-0.25	-0.24	0.39
EBT Excluding Unusual Items	1,071	936.67	668.13	367.77	227.69	127.51
Gain (Loss) on Sale of Investments	0.61	0.88	2.65	0.4	1.8	3.96
Gain (Loss) on Sale of Assets	-0.06	-0.03	-0.87	0.03	-1.8	-1.13
Asset Writedown	-	-	-12.76	-	-	-
Other Unusual Items	-30.33	-6.5	-16.49	-12.27	-12.4	8.73
Pretax Income	1,042	931.03	640.65	355.93	215.29	139.07
Income Tax Expense	90.55	103.42	85.21	68.91	34.09	22.5
Net Income	951.15	827.6	555.45	287.02	181.2	116.57
Net Income to Common	951.15	827.6	555.45	287.02	181.2	116.57
Net Income Growth	44.64%	49.00%	93.52%	58.40%	55.44%	81.31%
Shares Outstanding (Basic)	409	408	405	404	403	402
Shares Outstanding (Diluted)	409	408	405	404	403	402
Shares Change (YoY)	0.59%	0.56%	0.29%	0.39%	0.18%	12.54%
EPS (Basic)	2.33	2.03	1.37	0.71	0.45	0.29
EPS (Diluted)	2.33	2.03	1.37	0.71	0.45	0.29
EPS Growth	43.79%	48.18%	92.96%	57.78%	55.17%	61.11%
Free Cash Flow	499.38	179.28	223.64	143.99	43.85	-26.2
Free Cash Flow Per Share	1.22	0.44	0.55	0.36	0.11	-0.07
Dividend Per Share	0.620	0.620	0.410	0.213	0.100	0.050
Dividend Growth	51.22%	51.22%	92.49%	113.00%	100.00%	100.00%
Gross Margin	93.24%	93.45%	93.33%	88.80%	88.78%	89.21%
Operating Margin	33.26%	33.02%	31.42%	23.58%	19.57%	15.98%
Profit Margin	30.31%	29.38%	26.45%	18.80%	16.00%	14.68%
Free Cash Flow Margin	15.91%	6.36%	10.65%	9.43%	3.87%	-3.30%
EBITDA	1,112	989.71	713.25	403.23	260.33	165.03
EBITDA Margin	35.45%	35.13%	33.96%	26.41%	22.99%	20.79%
D&A For EBITDA	68.65	59.38	53.37	43.17	38.69	38.17
EBIT	1,044	930.33	659.88	360.06	221.64	126.86
EBIT Margin	33.26%	33.02%	31.42%	23.58%	19.57%	15.98%
Effective Tax Rate	8.69%	11.11%	13.30%	19.36%	15.83%	16.18%
Revenue as Reported	3,138	2,817	2,100	1,527	1,132	793.93
Advertising Expenses	-	-	-	2.94	5.48	6.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.